Thanks also hottod. It’s fascinating to see close up a competitor that is a few years ahead of PolyNovo.
I noticed several points of differentiation in Poly’s favour. Here’s just one:
the founder of Kerecis observed “we have over 40 studies and then then randomized controlled studies and we continue to invest in clinical work”.
This can be compared with the fact that the NovoSorb tech is covered by over 230 publications.
I wonder if Kerecis’s previous owners were keen to sell to Coloplast because they could see what was coming at them over the next few years…
PNV - Banter and General Comments, page-11350
-
- There are more pages in this discussion • 688 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.36 |
Change
0.020(0.85%) |
Mkt cap ! $1.628B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.40 | $2.33 | $1.160M | 491.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5181 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.36 | 1873 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |